Insourcing cell-line development has helped a fast-growing antibody manufacturer to deliver process improvements and strengthen communication with their contract manufacturer, according to Genmab, ...

WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and ...

In the race to bring new biologics to market, development teams are constantly balancing speed, quality, and regulatory ...

If you’ve ever had to pause a promising experiment while waiting on titer results, you’re not alone. In many labs, samples come off the bioreactor only to sit in line for ELISA or HPLC - and decisions ...

New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules SEATTLE--(BUSINESS WIRE)-- As drug ...

HanchorBio and WuXi Biologics collaborate to develop fusion proteins using the Fc-Based Designer Biologics platform, ...

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable ...

During a cell line development project, Agenus UK used the Amperia platform in combination with BLI and SPR to analyze antibody titers. The study found a good correlation between the platforms and ...

Aragen Biologics launched CHOMax™, a new cell line development and early manufacturing platform that the company says supports an integrated path from DNA to IND-enabling clinical supply for suitable ...

Successful commercialization of a biopharmaceutical product is dependent upon an effective, high-quality cell-line development process. While high-throughput analytical instruments often take center ...

Cell line development continues to face technical and operational hurdles in transfection, clone selection, and media optimization. Manual screening, extended culture timelines, and fragmented data ...